Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 25, 2017
Which drugs does patent 6,011,068 protect, and when does it expire?
| Title: | Calcium receptor-active molecules |
| Abstract: | The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca.sup.2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies. |
| Inventor(s): | Nemeth; Edward F. (Salt Lake City, UT), Van Wagenen; Bradford C. (Salt Lake City, UT), Balandrin; Manuel F. (Sandy, UT), DelMar; Eric G. (Salt Lake City, UT), Moe; Scott T. (Salt Lake City, UT) |
| Assignee: | NPS Pharmaceuticals, Inc. (Salt Lake City, UT) The Brigham and Women's Hospital (Boston, MA) |
| Application Number: | 08/353,784 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-001 | Mar 8, 2004 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | |||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-002 | Mar 8, 2004 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | |||
Amgen | SENSIPAR | cinacalcet hydrochloride | TABLET;ORAL | 021688-003 | Mar 8, 2004 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | |||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,391,210 | Abrasive article | ► Subscribe | |||||||||||||
| 6,211,244 | Calcium receptor-active compounds | ► Subscribe | |||||||||||||
| 6,313,146 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 6,031,003 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 5,858,684 | Method of screening calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 5,763,569 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 5,962,314 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 5,688,938 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| 6,001,884 | Calcium receptor-active molecules | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 264292 | ► Subscribe | |||||||||||||
| Austria | 287390 | ► Subscribe | |||||||||||||
| Austria | 312347 | ► Subscribe | |||||||||||||
| Austria | 313321 | ► Subscribe | |||||||||||||
| Austria | 359259 | ► Subscribe | |||||||||||||
| Australia | 1014100 | ► Subscribe | |||||||||||||
| Australia | 2588992 | ► Subscribe | |||||||||||||
| Australia | 3122699 | ► Subscribe | |||||||||||||
| Australia | 4195796 | ► Subscribe | |||||||||||||
| Australia | 673500 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,764 others who get our Drug Patent Expiration Alerts:
